These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 39368484)

  • 1. Gene therapy for diffuse pleural mesotheliomas in preclinical models by concurrent expression of NF2 and SuperHippo.
    Zhu R; Liu X; Zhang X; Zhong Z; Qi S; Jin R; Gu Y; Wang Y; Ling C; Chen K; Ye D; Yu FX
    Cell Rep Med; 2024 Oct; 5(10):101763. PubMed ID: 39368484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivation of
    Kukuyan AM; Sementino E; Kadariya Y; Menges CW; Cheung M; Tan Y; Cai KQ; Slifker MJ; Peri S; Klein-Szanto AJ; Rauscher FJ; Testa JR
    Cancer Res; 2019 Aug; 79(16):4113-4123. PubMed ID: 31151962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
    Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
    Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment and characterization of CRISPR/Cas9-mediated NF2
    Wahiduzzaman M; Karnan S; Ota A; Hanamura I; Murakami H; Inoko A; Rahman ML; Hyodo T; Konishi H; Tsuzuki S; Hosokawa Y
    Cancer Sci; 2019 Jan; 110(1):180-193. PubMed ID: 30417500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurofibromatosis Type 2-Yes-Associated Protein and Transcriptional Coactivator With PDZ-Binding Motif Dual Immunohistochemistry Is a Reliable Marker for the Detection of Neurofibromatosis Type 2 Alterations in Diffuse Pleural Mesothelioma.
    Li Y; Yang SR; Chen YB; Adusumilli PS; Bialik A; Bodd FM; Ladanyi M; Lopardo J; Offin MD; Rusch VW; Travis WD; Zauderer MG; Chang JC; Sauter JL
    Mod Pathol; 2023 Mar; 36(3):100030. PubMed ID: 36788094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation.
    Sekido Y
    Pathol Int; 2011 Jun; 61(6):331-44. PubMed ID: 21615608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing.
    Miyanaga A; Masuda M; Tsuta K; Kawasaki K; Nakamura Y; Sakuma T; Asamura H; Gemma A; Yamada T
    J Thorac Oncol; 2015 May; 10(5):844-851. PubMed ID: 25902174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-occurring Mutations of Tumor Suppressor Genes,
    Tranchant R; Quetel L; Tallet A; Meiller C; Renier A; de Koning L; de Reynies A; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D
    Clin Cancer Res; 2017 Jun; 23(12):3191-3202. PubMed ID: 28003305
    [No Abstract]   [Full Text] [Related]  

  • 9. Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma.
    Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Iwasaki A; Nabeshima K
    Mod Pathol; 2020 Feb; 33(2):235-244. PubMed ID: 31231129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models.
    Hillen H; Candi A; Vanderhoydonck B; Kowalczyk W; Sansores-Garcia L; Kesikiadou EC; Van Huffel L; Spiessens L; Nijs M; Soons E; Haeck W; Klaassen H; Smets W; Spieser SA; Marchand A; Chaltin P; Ciesielski F; Debaene F; Chen L; Kamal A; Gwaltney SL; Versele M; Halder GA
    Mol Cancer Ther; 2024 Jan; 23(1):3-13. PubMed ID: 37748190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation.
    Matsushita A; Sato T; Mukai S; Fujishita T; Mishiro-Sato E; Okuda M; Aoki M; Hasegawa Y; Sekido Y
    Oncogene; 2019 Mar; 38(11):1966-1978. PubMed ID: 30401981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NF2/Merlin Inactivation and Potential Therapeutic Targets in Mesothelioma.
    Sato T; Sekido Y
    Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29587439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LIM-domain protein AJUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascade.
    Tanaka I; Osada H; Fujii M; Fukatsu A; Hida T; Horio Y; Kondo Y; Sato A; Hasegawa Y; Tsujimura T; Sekido Y
    Oncogene; 2015 Jan; 34(1):73-83. PubMed ID: 24336325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant expression of NPPB through YAP1 and TAZ activation in mesothelioma with Hippo pathway gene alterations.
    Sato T; Akao K; Sato A; Tsujimura T; Mukai S; Sekido Y
    Cancer Med; 2023 Jun; 12(12):13586-13598. PubMed ID: 37165917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WWC proteins mediate LATS1/2 activation by Hippo kinases and imply a tumor suppression strategy.
    Qi S; Zhu Y; Liu X; Li P; Wang Y; Zeng Y; Yu A; Wang Y; Sha Z; Zhong Z; Zhu R; Yuan H; Ye D; Huang S; Ling C; Xu Y; Zhou D; Zhang L; Yu FX
    Mol Cell; 2022 May; 82(10):1850-1864.e7. PubMed ID: 35429439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.
    Li W; Cooper J; Zhou L; Yang C; Erdjument-Bromage H; Zagzag D; Snuderl M; Ladanyi M; Hanemann CO; Zhou P; Karajannis MA; Giancotti FG
    Cancer Cell; 2014 Jul; 26(1):48-60. PubMed ID: 25026211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of NF2 hemizygous loss detected by fluorescence in situ hybridization in diagnosing pleural mesothelioma in tissue and cytology material: A multi-institutional study.
    Sa-Ngiamwibool P; Hamasaki M; Kinoshita Y; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Kasai T; Kushitani K; Takeshima Y; Hiroshima K; Iwasaki A; Nabeshima K
    Lung Cancer; 2023 Jan; 175():27-35. PubMed ID: 36442384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hippo pathway inactivation through subcellular localization of NF2/merlin in outer cells of mouse embryos.
    Goda N; Ito Y; Saito S; Suzuki M; Bai H; Takahashi M; Wakai T; Kawahara M
    Development; 2024 Jul; 151(14):. PubMed ID: 39077779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A critical role for NF2 and the Hippo pathway in branching morphogenesis.
    Reginensi A; Enderle L; Gregorieff A; Johnson RL; Wrana JL; McNeill H
    Nat Commun; 2016 Aug; 7():12309. PubMed ID: 27480037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The tumor suppressor NF2 modulates TEAD4 stability and activity in Hippo signaling via direct interaction.
    Wu M; Hu L; He L; Yuan L; Yang L; Zhao B; Zhang L; He X
    J Biol Chem; 2024 May; 300(5):107212. PubMed ID: 38522513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.